Lipid-regulatory Efficacy and Safety of Rosuvastatin (10mg?d~(-1)) for Chinese Population:A Meta-analysis / 中国药房

ABSTRACT

OBJECTIVE:To evaluate the lipid-regulatory efficacy and safety of rosuvastatin (10 mg?d-1) for Chinese population. METHODS: The pertinent literature comparing the serum blood lipid level before and after treatment with rosuvastatin (10 mg?d-1) between 2001 and 2008 were collected by retrieving Wanfang database,CNKI,Weipu electronic periodicals;and the data were given a meta-analysis using RevMan 4.2 software,meanwhile the safety of rosuvastatin was evaluated. RESULTS: A total of 346 patients were enrolled in 5 trials. After treatment with rosuvastatin (10 mg?d-1),the low density lipoproteincholesterol(LDL-C) was lowered by 1.71 mmol?L-1 on average;the total cholesterol (TC) was lowered by 1.98 mmol?L-1 on average;high density lipoprotein cholesterol(HDL-C) was increased by 0.17 mmol?L-1 on average;and the level of triglyeride was lowered by 0.79 mmol?L-1 on average. A total of 54 adverse events were reported,and the adverse drug reactions manifested chiefly as upper respiratory infection,mild notalgia,debilitation and gastrointestinal upset. No severe side effects were reported. CONCLUSION: It has been confirmed by domestic clinical trials that rosuvastatin(10 mg?d-1) is safe and effective for Chinese population.